Welcome to our dedicated page for Penumbra SEC filings (Ticker: PEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Penumbra, Inc. filings document the regulatory record for a NYSE-listed medical-device company focused on thrombectomy technologies for stroke, pulmonary embolism, venous thromboembolism, and acute limb ischemia. Form 8-K reports cover operating results, material-event disclosures, material agreements, capital-structure matters, and clinical or regulatory updates involving its thrombectomy portfolio.
Proxy materials describe shareholder voting matters, governance practices, compensation arrangements, and capital-structure proposals. The filing record also includes disclosures on risk factors, financial condition, executive appointments and compensatory arrangements, and the company's common stock registered under the symbol PEN on the New York Stock Exchange.
Penumbra, Inc. insider Harpreet Grewal has filed a notice of proposed sale under Rule 144 for 186 shares of common stock, with an aggregate market value of 58,151.04. The shares are to be sold through Fidelity Brokerage Services LLC on the NYSE around January 6, 2026, and Penumbra has 39,162,177 shares of common stock outstanding.
The 186 shares to be sold were acquired as a stock award from Penumbra on December 31, 2025. Over the prior three months, the same seller disposed of 186 shares on November 4, 2025 for 42,329.88 and 100 shares on December 2, 2025 for 29,298.00. By signing the notice, the seller represents that they do not know of any material adverse, nonpublic information about Penumbra’s operations.
A holder of PEN common stock has filed a notice to potentially sell shares under Rule 144. The filing covers the planned sale of 186 common shares through Morgan Stanley Smith Barney LLC Executive Financial Services on the NYSE, with an indicated aggregate market value of $57,793.92. The issuer had 39,162,177 shares outstanding at the time referenced. The shares to be sold were acquired as restricted stock from the issuer on 12/31/2025, with payment also dated 12/31/2025.
Penumbra Inc's chief financial officer, Maggie Yuen, reported a tax-related share withholding tied to her equity compensation. On 12/15/2025, 565 shares of Penumbra common stock were withheld by the company at a price of $309.15 per share, identified with transaction code F for tax withholding.
After this transaction, Yuen beneficially owned 16,006 Penumbra shares, some of which remain subject to vesting. The total includes 15 shares purchased under Penumbra's Employee Stock Purchase Plan on November 19, 2025. The filing characterizes the withholding as satisfying tax obligations arising from the vesting of restricted stock units previously granted to her.
Penumbra’s chief accounting officer, Lambert Shiu, reported an insider transaction involving 300 shares of common stock on 12/15/2025. The 300 shares were withheld by the company to cover tax withholding obligations triggered by the vesting of restricted stock units previously granted to him.
After this transaction, Shiu beneficially owns 35,285 Penumbra common shares directly, with a portion of these shares still subject to vesting and including 20 shares purchased under the company’s Employee Stock Purchase Plan on November 19, 2025. He also indirectly owns 300 shares held in his spouse’s IRA.
Penumbra Inc. executive Johanna Roberts, EVP, General Counsel & Secretary, reported a tax-related share withholding tied to equity compensation. On 12/15/2025, 1,130 shares of Penumbra common stock were disposed of at $309.15 per share under transaction code F, which indicates shares withheld to satisfy tax obligations on vesting restricted stock units.
After this transaction, she beneficially owns 62,706 shares of Penumbra common stock, and a portion of these shares remains subject to vesting. No derivative securities transactions were reported.
Penumbra Inc. director Arani Bose reported multiple open-market sales of Penumbra common stock on 12/11/2025, carried out under a pre-arranged Rule 10b5-1 trading plan. The transactions, all coded as sales, were executed in several tranches, including 2,030 shares at a weighted average price of $305.19, 4,946 shares at $306.6, and 3,523 shares at $311.47, with other trades priced in the general range of $305–$312 per share.
Following one of the reported transactions, the filing shows 258,462 shares of Penumbra common stock beneficially owned indirectly through Bose Family Holdings II, LLC, and a portion of these shares is subject to vesting. The filing emphasizes that several trades were executed in multiple lots within stated price ranges, with the weighted average prices reported and full trade details available upon request.
Penumbra Inc. executive vice president, general counsel and secretary reported a small stock sale under a pre-arranged trading plan. On 12/05/2025, the reporting person sold 300 shares of Penumbra common stock at a weighted average price of $300.13 per share under a Rule 10b5-1 trading plan, which allows preset trades to occur over time. After this transaction, the insider beneficially owned 63,836 shares of Penumbra common stock, a portion of which remains subject to vesting.
Penumbra, Inc. reported insider trading activity by its EVP, General Counsel & Secretary, Johanna Roberts. On 12/01/2025, she executed several small open-market sales of Penumbra common stock under a pre-arranged Rule 10b5-1 trading plan. The reported weighted average sale prices ranged from about $292.09 to $298.02 per share across multiple trades. After these transactions, she beneficially owned 64,136 shares of Penumbra common stock, and a portion of these shares is subject to vesting. All sales were reported as directly owned shares.
Penumbra, Inc. director reports small stock sale under 10b5-1 plan
A Penumbra Inc (ticker PEN) director reported selling 100 shares of common stock on 12/02/2025 at a price of $292.98 per share. After this transaction, the reporting person beneficially owns 8,416 shares of Penumbra common stock. The filing notes that the sale was executed under the director’s pre-established Rule 10b5-1 trading plan, which is designed to permit scheduled trades. The company also discloses that a portion of the remaining shares is still subject to vesting conditions.
Penumbra insider Harpreet Grewal has filed a notice to sell company stock under Rule 144. The notice covers 100 shares of Penumbra common stock to be sold through Fidelity Brokerage Services on the NYSE, with an approximate sale date of 12/02/2025. The stock was originally acquired on 03/26/2006 in a private purchase from Penumbra for cash.
The filing also lists recent sales by the same seller over the prior three months: 186 shares of common stock on 09/02/2025 for gross proceeds of 50,627.34, another 186 shares on 10/02/2025 for 46,241.46, and 186 shares on 11/04/2025 for 42,329.88. Penumbra had 38,999,129 shares of common stock outstanding at the time indicated, which provides context for the scale of these transactions.